What does CUSIP 230031106 represent in this 13F holders report?

CUSIP 230031106 is the security identifier for CGEM - Cullinan Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held CGEM - Cullinan Therapeutics, Inc. - Common Stock in Q2 2023?

102 institutional investors reported CGEM - Cullinan Therapeutics, Inc. - Common Stock for Q2 2023. Use the holders table for investor-level position and value details.

Cullinan Therapeutics, Inc. - Common Stock (CGEM)

CUSIP: 230031106

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock
Shares outstanding: 59,091,689
Total 13F shares: 36,693,312
Share change: +4,483,983
Total reported value: $394,818,289
Put/Call ratio: 1139%
Price per share: $10.76
Number of holders: 102
Value change: +$48,696,476
Number of buys: 52
Number of sells: 56

Quarterly Holders Quick Answers

What is CUSIP 230031106?
CUSIP 230031106 identifies CGEM - Cullinan Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 230031106:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CGEM - Cullinan Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Ansbert Gadicke	3/4/5	Director	— class O/S missing	8,243,757	$102,717,212	—	22 Jun 2022	3/4/5
UBS Oncology Impact Fund L.P.	3/4/5	10%+ Owner	— class O/S missing	7,648,268	$95,297,419	—	16 Sep 2021	3/4/5
MPM BioImpact LLC	13F	Company	13%	7,648,268	$78,241,782	—	31 Mar 2023	13F
Morana Jovan-Embiricos	3/4/5	10%+ Owner	— class O/S missing	4,526,260	$56,397,201	—	24 Jun 2022	3/4/5
Vision Scs F2	3/4/5	10%+ Owner	— class O/S missing	4,476,350	$55,775,322	—	02 Aug 2022	3/4/5
F2 Bioscience I 2017 Ltd	3/4/5	10%+ Owner	— class O/S missing	4,430,964	$55,209,813	—	21 Jun 2022	3/4/5
CHI Advisors LLC	13F	Company	5.7%	3,349,460	$34,264,977	—	31 Mar 2023	13F
BVF INC/IL	13F	Company	5.4%	3,196,701	$32,702,251	—	31 Mar 2023	13F
VANGUARD GROUP INC	13F	Company	4.3%	2,554,988	$26,137,527	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	3.8%	2,255,597	$23,074,757	—	31 Mar 2023	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	2.1%	1,236,349	$12,647,851	—	31 Mar 2023	13F
Nextech Invest Ltd.	13F	Company	2.1%	1,221,145	$12,492,313	—	31 Mar 2023	13F
Boxer Capital, LLC	13F	Company	1.8%	1,074,082	$10,988,000	—	31 Mar 2023	13F
FRANKLIN RESOURCES INC	13F	Company	1.3%	789,138	$8,072,880	—	31 Mar 2023	13F
Rubric Capital Management LP	13F	Company	1.1%	626,929	$6,413,484	—	31 Mar 2023	13F
CITADEL ADVISORS LLC	13F	Company	1.1%	623,068	$6,373,986	—	31 Mar 2023	13F
ORBIMED ADVISORS LLC	13F	Company	1%	605,387	$6,193,109	—	31 Mar 2023	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.99%	584,942	$5,983,957	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	0.95%	562,214	$5,751,449	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.91%	537,823	$5,501,929	—	31 Mar 2023	13F
Patrick Baeuerle	3/4/5	Chief Scientific Officer	— mixed-class rows	494,434 mixed-class rows	$5,201,228	—	17 Feb 2023	3/4/5
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.85%	500,000	$5,115,000	—	31 Mar 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.59%	346,219	$3,541,820	—	31 Mar 2023	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.55%	322,928	$3,293,866	—	31 Mar 2023	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.45%	265,032	$2,711,277	—	31 Mar 2023	13F
Artal Group S.A.	13F	Company	0.42%	250,000	$2,558,000	—	31 Mar 2023	13F
NORTHERN TRUST CORP	13F	Company	0.42%	248,578	$2,542,953	—	31 Mar 2023	13F
EcoR1 Capital, LLC	13F	Company	0.42%	246,410	$2,520,774	—	31 Mar 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.41%	244,553	$2,502,000	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.4%	239,200	$2,447,000	—	31 Mar 2023	13F
Assenagon Asset Management S.A.	13F	Company	0.37%	221,340	$2,264,308	—	31 Mar 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.32%	187,533	$1,918,463	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.3%	179,820	$1,839,558	—	31 Mar 2023	13F
Parkman Healthcare Partners LLC	13F	Company	0.29%	169,886	$1,737,934	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.28%	165,948	$1,697,648	—	31 Mar 2023	13F
Atom Investors LP	13F	Company	0.2%	120,109	$1,228,715	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.17%	101,052	$1,033,761	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.16%	96,240	$984,536	—	31 Mar 2023	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.15%	88,292	$903,227	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.15%	86,201	$881,836	—	31 Mar 2023	13F
Leigh Zawel	3/4/5	Chief Scientific Officer, Small Molecules	— mixed-class rows	134,785 mixed-class rows	$869,521	—	11 Feb 2022	3/4/5
BVF PARTNERS L P/IL	3/4/5	10%+ Owner	— mixed-class rows	94,161 mixed-class rows	$799,446	—	19 Jan 2023	3/4/5
Hudson Bay Capital Management LP	13F	Company	0.13%	75,000	$767,250	—	31 Mar 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.12%	73,572	$752,642	—	31 Mar 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.12%	72,208	$739,000	—	31 Mar 2023	13F
VIRGINIA RETIREMENT SYSTEMS ET Al	13F	Company	0.1%	61,900	$633,237	—	31 Mar 2023	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.1%	59,832	$612,082	—	31 Mar 2023	13F
FMR LLC	13F	Company	0.09%	54,272	$555,203	—	31 Mar 2023	13F
RHUMBLINE ADVISERS	13F	Company	0.09%	51,093	$523,000	—	31 Mar 2023	13F
Ergoteles LLC	13F	Company	0.08%	48,622	$497,403	—	31 Mar 2023	13F

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q2 2023

As of 30 Jun 2023, Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by 102 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 36,693,312 shares. The largest 10 holders included BIOIMPACT CAPITAL LLC, CHI Advisors LLC, BVF INC/IL, FRANKLIN RESOURCES INC, BlackRock Inc., VANGUARD GROUP INC, BRAIDWELL LP, AMERICAN INTERNATIONAL GROUP, INC., Nextech Invest Ltd., and ADAGE CAPITAL PARTNERS GP, L.L.C.. This page lists 102 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

102

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.